awmsg logo



ipilimumab (Yervoy®)


Reference No. 3604

Publication date:
06/11/2018


Appraisal information

ipilimumab (Yervoy®) 5 mg/ml concentrate for solution for infusion


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 05/09/2018
AWMSG meeting date: 17/10/2018
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1818
Ratification by Welsh Government: 02/11/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Ipilimumab (Yervoy®) is recommended as an option for use within NHS Wales as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age to < 18 years of age. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download